Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Carboplatin in Recurrent Ovarian Cancer
NCT04387227Phase 2Completed
- Sponsor
- University of Washington
- Start
- Mar 2021
- Primary completion
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by University of Washington. Started Mar 2021; status: completed.
02
Drugs
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04387227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04387227.